公开(公告)号：US09676849B2

公开(公告)日：2017-06-13

申请号：US14370828

申请日：2013-01-10

Applicant: Biogen Idec MA Inc.

Inventor： Graham K. Farrington ,  William Sisk

IPC: A61K39/00 ,  C07K16/28 ,  C07K16/46 ,  C07K14/415 ,  C07K14/47

CPC classification number: C07K16/28 ,  A61K39/00 ,  A61K2039/505 ,  C07K14/415 ,  C07K14/4702 ,  C07K16/46 ,  C07K2317/22 ,  C07K2317/569 ,  C07K2317/64 ,  C07K2317/70 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/33

Abstract: The invention is based, at least in part, on the finding that a dimeric version of a BBB-transmigrating antibody (e.g., the TMEM30A (CDC-50A) binding antibody, FC5) was found to greatly enhance transport across the BBB as compared to monovalent FC5 VHH. The invention provides, inter alia, molecules that increase transport of pharmacologically active agents across the blood brain barrier, methods for increasing transport across the blood brain barrier, and methods of treatment of disorders or diseases having a neurological component.

公开(公告)号：US20130101549A1

公开(公告)日：2013-04-25

申请号：US13660238

申请日：2012-10-25

Applicant: BIOGEN IDEC MA INC.

Inventor： Xinzhong Wang ,  Veronique Bailly ,  Graham K. Farrington ,  Alexey Lugovskoy

IPC: C07K16/30 ,  C07K14/525

CPC classification number: C07K16/30 ,  C07K14/525 ,  C07K14/7151 ,  C07K2319/01 ,  G01N33/57415

Abstract: LIGHT-targeting molecules (e.g., LIGHT fusion molecules), compositions, e.g., pharmaceutical compositions thereof, are disclosed. Methods of using these molecules to treat, prevent and/or diagnose hyperproliferative, e.g., neoplastic, diseases or conditions, including, but not limited to, cancer and metastasis are also provided.

Abstract translation: 公开了光靶向分子（例如，LIGHT融合分子），组合物，例如其药物组合物。 还提供了使用这些分子来治疗，预防和/或诊断过度增殖，例如肿瘤性疾病或病症（包括但不限于癌症和转移）的方法。

公开(公告)号：US20150210762A1

公开(公告)日：2015-07-30

申请号：US14370828

申请日：2013-01-10

Applicant: Biogen Idec MA Inc.

Inventor： Graham K. Farrington ,  William Sisk

IPC: C07K16/28 ,  C07K14/47 ,  C07K16/46

CPC classification number: C07K16/28 ,  A61K39/00 ,  A61K2039/505 ,  C07K14/415 ,  C07K14/4702 ,  C07K16/46 ,  C07K2317/22 ,  C07K2317/569 ,  C07K2317/64 ,  C07K2317/70 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/33

Abstract: The invention is based, at least in part, on the finding that a dimeric version of a BBB-transmigrating antibody (e.g., the TMEM30A (CDC-50A) binding antibody, FC5) was found to greatly enhance transport across the BBB as compared to monovalent FC5 VHH. The invention provides, inter alia, molecules that increase transport of pharmacologically active agents across the blood brain barrier, methods for increasing transport across the blood brain barrier, and methods of treatment of disorders or diseases having a neurological component.

Abstract translation: 本发明至少部分地基于以下发现：发现BBB转移抗体（例如，TMEM30A（CDC-50A）结合抗体FC5）的二聚体版本被大大增强穿过BBB的转运，与 单价FC5 VHH。 本发明尤其提供增加药物活性剂跨越血脑屏障的转运的分子，增加穿过血脑屏障的转运的方法，以及具有神经学成分的病症或疾病的治疗方法。